Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · IEX Real-Time Price · USD
42.55
-0.23 (-0.54%)
At close: Jul 19, 2024, 4:00 PM
42.50
-0.05 (-0.12%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Ultragenyx Pharmaceutical Revenue
Ultragenyx Pharmaceutical had revenue of $442.59M in the twelve months ending March 31, 2024, with 15.29% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $108.83M with 8.30% year-over-year growth. In the year 2023, Ultragenyx Pharmaceutical had annual revenue of $434.25M with 19.52% growth.
Revenue (ttm)
$442.59M
Revenue Growth
+15.29%
P/S Ratio
8.71
Revenue / Employee
$346,854
Employees
1,276
Market Cap
3.85B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 434.25M | 70.92M | 19.52% |
Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
Dec 31, 2019 | 103.71M | 52.22M | 101.41% |
Dec 31, 2018 | 51.50M | 48.88M | 1,871.48% |
Dec 31, 2017 | 2.61M | 2.48M | 1,863.91% |
Dec 31, 2016 | 133.00K | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Perrigo Company | 4.56B |
Surgery Partners | 2.79B |
Integer Holdings | 1.63B |
Sotera Health Company | 1.08B |
Waystar Holding | 824.72M |
Inspire Medical Systems | 660.91M |
Guardant Health | 603.73M |
Axsome Therapeutics | 251.02M |
RARE News
- 2 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 weeks ago - Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 weeks ago - Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) - GlobeNewsWire
- 5 weeks ago - Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) - GlobeNewsWire
- 6 weeks ago - Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewsWire
- 2 months ago - Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference - GlobeNewsWire